SCHEMBL1569930

SCHEMBL1569930

CC(C)(C)OC(=O)NCCc1ccc(COS(C)(=O)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA2 P00918 12/20 0.56
CA1 P00915 9/20 0.56
NAMPT P43490 1/20 0.49
NQO2 P16083 1/20 0.47
CA12 O43570 5/20 0.44
CA9 Q16790 5/20 0.44
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SYK P43405 1/20 0.42
LMNA P02545 1/20 0.42
PTGER4 P35408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30898273 0.87 NQO2 (0.52) CA2CA1NAMPTNQO2CA12
SCHEMBL19716620 0.86 CA1 (0.50) CA2CA1NAMPTCA12MAPT
SCHEMBL2000568 0.84 CA2 (0.56) CA2CA1NAMPTNQO2CA12
SCHEMBL100146 0.83 KDM4E (0.60) CA2CA1NAMPTNQO2MAPT
SCHEMBL17960773 0.82 CA1 (0.67) CA2CA1CA12CA9TDP1
SCHEMBL12029116 0.82 CA2 (0.56) CA2CA1NAMPTNQO2CA12
SCHEMBL30898244 0.82 NQO2 (0.57) CA2CA1NAMPTNQO2CA12
SCHEMBL30439339 0.81 CA2 (0.58) CA2CA1NAMPTNQO2CA12
SCHEMBL12641164 0.81 CA2 (0.56) CA2CA1NAMPTLMNA
SCHEMBL3375330 0.81 CYP17A1 (0.53) CA2CA1NAMPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144303-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES Array Biopharma, Inc. (US) 2017-03-22 EP disclosed
US-9556139-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2017-01-31 US disclosed
EP-2826774-B1 Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC (US) 2016-05-25 EP disclosed
US-20150232442-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2015-08-20 US disclosed
US-9096567-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2015-08-04 US disclosed
CN-103450138-B Preparation of intermidiates of 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2015-04-08 CN disclosed
EP-2826774-A1 Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives Array Biopharma, Inc. (US) 2015-01-21 EP disclosed
EP-2307397-B1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2014-08-20 EP disclosed
US-20140221342-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2014-08-07 US disclosed
US-8716498-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA, INC. (US) 2014-05-06 US disclosed
US-20140005418-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2014-01-02 US disclosed
CN-103450138-A Preparation of intermidiates of 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2013-12-18 CN disclosed
US-8569522-B2 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2013-10-29 US disclosed
CN-102131794-B 6-substituted phenoxy chroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2013-09-25 CN disclosed
CN-102131794-A 6-substituted phenoxy chroman carboxylic acid derivatives ARRAY BIOPHARMA INC 2011-07-20 CN disclosed
US-20110105463-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2011-05-05 US disclosed
EP-2307397-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES Array Biopharma, Inc. (US) 2011-04-13 EP disclosed
WO-2009158426-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221342-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES HRH1, HRH2, HRH4 CA2 1292/4885CA1 2478/4885NAMPT 3868/4885
US-20110105463-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES GPR52, CD22, CD4 CA2 1332/4885CA1 2986/4885NAMPT 4818/4885
US-20150232442-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES GPR52, CD22, CD74 CA2 1303/4885CA1 3221/4885NAMPT 4811/4885
US-20140005418-A1 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES UGT1A6, UGT2B7, UGT1A7 CA2 1651/4885CA1 604/4885NAMPT 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.